BRIEF DESCRIPTION OF THE ORGANIZATION
Akthelia Pharma is an Icelandic late preclinical-stage immunotherapy firm, targetting major cancer and transplant challenges by mitigating neutropenic sepsis risk. This life-threatening complication from anticancer treatment, leading to up to 20% mortality excluding disease progression, results from neutrophil count reduction and GI integrity loss. We’ve innovated a patented approach backed by top KOLs to enhance GI tract immunity and integrity, effectively blocking bacterial translocation, the main causal pathophysiology. Our patents also pave the way for an out-licensing platform for various indications, creating a pipeline and lessening dilutive financing needs for our lead program.
WHAT IS YOUR ROLE IN THE PROJECT?
Lead molecule candidate optimisation, synthesis & shortlisting. Participate in all other work packages. Akthelia Pharmaceuticals will lead the first work package, which includes molecule candidate optimisation, synthesis & shortlisting. Akthelia’s expertise in therapeutic discovery and development will continue to guide and oversee the work undertaken in subsequent packages, from WP2 to WP8.